Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | THPO | P40225 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL10528253 | 0.93 | TDP1 (0.57) | TDP1CA2KDM4EHIF1ACYP3A4 | |
| Sulfuric Acid SCHEMBL16470839 | 0.90 | TDP1 (0.53) | TDP1CA2KDM4EHIF1ACYP3A4 | |
| Sulfuric Acid SCHEMBL9550776 | 0.90 | TDP1 (0.53) | TDP1CA2KDM4EHIF1ACYP3A4 | |
| Sulfuric Acid SCHEMBL16344486 | 0.90 | TDP1 (0.53) | TDP1CA2KDM4EHIF1ACYP3A4 | |
| SCHEMBL28360936 | 0.79 | TDP1 (0.57) | TDP1 | |
| SCHEMBL23451648 | 0.78 | TDP1 (0.39) | TDP1 | |
| SCHEMBL575531 | 0.77 | CA2 (0.44) | TDP1CA2KDM4ECYP3A4LMNA | |
| Isopropyl Alcohol SCHEMBL9431191 | 0.77 | — | — | |
| Hydrogen Peroxide SCHEMBL135017 | 0.76 | TDP1 (0.80) | TDP1LMNAGAATP53ALDH1A1 | |
| Methyl Alcohol SCHEMBL2170375 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3684749-A1 | CATALYTIC CYCLE FOR PRODUCTION OF 1,1-DISUBSTITUTED ALKENES | Sirrus, Inc. (US) | 2020-07-29 | — | — | EP | claimed |
| US-20200223779-A1 | CATALYTIC CYCLE FOR PRODUCTION OF 1,1-DISUBSTITUTED ALKENES | SIRRUS, INC. | 2020-07-16 | — | — | US | claimed |
| CN-111108087-A | Catalytic recycle for production of 1, 1-disubstituted olefins | 赛鲁斯股份有限公司 | 2020-05-05 | — | — | CN | claimed |
| WO-2019060188-A1 | CATALYTIC CYCLE FOR PRODUCTION OF 1,1-DISUBSTITUTED ALKENES | SIRRUS, INC. (US) | 2019-03-28 | — | — | WO | claimed |
| EP-3684749-A1 | CATALYTIC CYCLE FOR PRODUCTION OF 1,1-DISUBSTITUTED ALKENES | Sirrus, Inc. (US) | 2020-07-29 | — | — | EP | disclosed |
| US-20200223779-A1 | CATALYTIC CYCLE FOR PRODUCTION OF 1,1-DISUBSTITUTED ALKENES | SIRRUS, INC. | 2020-07-16 | — | — | US | disclosed |
| CN-111108087-A | Catalytic recycle for production of 1, 1-disubstituted olefins | 赛鲁斯股份有限公司 | 2020-05-05 | — | — | CN | disclosed |
| WO-2019060188-A1 | CATALYTIC CYCLE FOR PRODUCTION OF 1,1-DISUBSTITUTED ALKENES | SIRRUS, INC. (US) | 2019-03-28 | — | — | WO | disclosed |
| EP-0703221-B1 | 5 alpha-reductase Inhibitors | LILLY CO ELI (US) | 2002-03-27 | — | — | EP | disclosed |
| US-6150375-A | INHIBITORS OF BOTH OF THE HUMAN 5AR ISOZYMES; BENIGN PROSTATE HYPERPLASIA, MALE PATTERN BALDNESS, ACNE VULGARIS, SEBORRHEA, ANDROGENIC ALOPECIA, HIRSUTISM AND PROSTATE CANCER; BLOCKS THE CONVERSION OF TESTOSTERONE TO 5-ALPHA-DIHYDROTESTOSTERONE | ELI LILLY AND COMPANY (US) | 2000-11-21 | — | — | US | disclosed |
| EP-0684234-B1 | Synthesis of benzoquinolinones | LILLY CO ELI (US) | 2000-07-26 | — | — | EP | disclosed |
| CN-1163565-A | 5 alpha-reductase inhibitors | LILLY CO ELI (US) | 1997-10-29 | — | — | CN | disclosed |
| WO-1996036610-A1 | SYNTHESIS OF BENZOQUINOLINONES | ELI LILLY AND COMPANY (US) | 1996-11-21 | — | — | WO | disclosed |
| EP-0743303-A1 | Synthesis of bezoquinolinones | ELI LILLY AND COMPANY (US) | 1996-11-20 | — | — | EP | disclosed |
| WO-1996035422-A1 | METHODS FOR INHIBITING BONE LOSS | ELI LILLY AND COMPANY (US) | 1996-11-14 | — | — | WO | disclosed |
| EP-0742010-A2 | Benzoquinolin-3-ones to inhibit bone loss | ELI LILLY AND COMPANY (US) | 1996-11-13 | — | — | EP | disclosed |
| US-5574160-A | Syntheis of benzoquinolinones | ELI LILLY AND COMPANY (US) | 1996-11-12 | — | — | US | disclosed |
| EP-0733365-A2 | Use of benzoquinolin-3-ones for the treatment and prevention of prostatic cancer | ELI LILLY AND COMPANY (US) | 1996-09-25 | — | — | EP | disclosed |
| US-5550134-A | ADMINISTERING TO A MAMMAL FROM A SERIES OF BENZOQUINOLIN-3-ONE COMPOUNDS | ELI LILLY AND COMPANY (US) | 1996-08-27 | — | — | US | disclosed |
| EP-0703221-A1 | 5 alpha-reductase Inhibitors | ELI LILLY AND COMPANY (US) | 1996-03-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200223779-A1 | CATALYTIC CYCLE FOR PRODUCTION OF 1,1-DISUBSTITUTED ALKENES | ME1, ME3, ME2 | ADRB2 3858/4885TDP1 1568/4885CA2 198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.